复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发

中访网数据2025-12-23

中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。该药品于2019年有条件获批上市，但其药品注册证书已于2024年11月到期，目前正进行上市...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593459642?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2593459642","market":"hk","top_or_hot":-1,"title":"复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发","media":"中访网数据","content":"<div>\n<p>中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。该药品于2019年有条件获批上市，但其药品注册证书已于2024年11月到期，目前正进行上市...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药拟14.12亿元控股绿谷医药，押注阿尔茨海默病新药后续研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b><strong>中访网数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。该药品于2019年有条件获批上市，但其药品注册证书已于2024年11月到期，目前正进行上市...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","article_id":"2593459642","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223000126a46b26b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2593459642","pubTimestamp":1766419200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1593":"医美概念股","BK1574":"生物医药B类股","02196":"复星医药"},"translate_title":"Fosun Pharma plans to hold Green Valley Pharmaceutical for 1.412 billion yuan, betting on the follow-up research and development of new drugs for Alzheimer's disease","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":1.5,"02196":1.5},"content_text":"中访网数据上海复星医药（集团）股份有限公司近日发布公告，回复上海证券交易所关于其对外投资事项的监管工作函。核心信息显示，复星医药拟出资共计14.12亿元，通过受让股权及认购新增注册资本的方式，取得上海绿谷医药有限公司51%的控股权。此次交易的核心标的为绿谷医药旗下已暂停销售的阿尔茨海默病治疗药物甘露特钠胶囊。该药品于2019年有条件获批上市，但其药品注册证书已于2024年11月到期，目前正进行上市后确证性临床试验，预计2027年底完成患者入组，2029年上半年提交临床试验总结报告。复星医药表示，此次收购旨在丰富其中枢神经系统疾病治疗领域的产品管线。然而，公告也揭示了多项风险：甘露特钠胶囊的临床试验能否成功、能否重新获批上市及未来销售情况均存在不确定性；本次收购预计将产生较大商誉，未来存在减值风险；此外，绿谷医药曾因商业推广违规被处以罚款。为控制风险，本次投资款将分两期支付，首期6.35亿元于交割日投入，剩余6.35亿元将在三年内视研发进展支付。交易完成后，复星医药将主导标的公司的运营整合。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593459642","isCrawlerRequest":true}